What is Adicet Bio?
Adicet Bio is a pre-clinical stage biotechnology enterprise dedicated to the design and development of allogeneic immunotherapies. By focusing on off-the-shelf cell therapies, the company aims to overcome the limitations of traditional autologous treatments, offering a more scalable and accessible solution for patients suffering from cancer and other severe diseases. Headquartered in Boston, the firm utilizes advanced engineering to create potent, standardized therapeutic products that can be deployed rapidly in clinical settings. Its market position is defined by its specialized focus on gamma delta T cells, a unique subset of immune cells that offer significant potential for tumor recognition and destruction, thereby placing Adicet Bio at the forefront of next-generation oncology research.
How much funding has Adicet Bio raised?
Adicet Bio has raised a total of $218M across 3 funding rounds:
Series A
$51M
Series B
$80M
Stock Offering
$87M
Series A (2016): $51M with participation from OrbiMed, Pontifax, and Novartis Venture Fund
Series B (2019): $80M led by OrbiMed Israel, Pontifax, Novartis Venture Fund, and OrbiMed Partners
Stock Issuance/Offering (2021): $87M, investors not publicly disclosed
Key Investors in Adicet Bio
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation at various development stages.
Pontifax
Pontifax Venture Capital specializes in groundbreaking innovations in life sciences, providing hands-on guidance and strategic direction to disruptive startups in the healthcare and biotechnology sectors.
Novartis Venture Fund
The venture arm of a global pharmaceutical manufacturer, this fund focuses on research and development of innovative medications and healthcare solutions to improve patient outcomes worldwide.
What's next for Adicet Bio?
With the recent capital injection, Adicet Bio is poised to prioritize the advancement of its lead candidates through critical clinical trials. The strategic focus will likely shift toward optimizing manufacturing processes for its allogeneic platforms and expanding its internal research capabilities to explore new therapeutic indications. As the company moves deeper into the clinical development lifecycle, the emphasis will remain on demonstrating safety and efficacy profiles that justify further investment and potential future partnerships. The firm's ability to maintain its momentum will be contingent upon its success in navigating the regulatory environment and achieving key data readouts that validate its unique approach to immunotherapy.
See full Adicet Bio company page
